| Date | Filer | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|
| May 12, 2021 |
Director, President and CEO
Trans History: 14
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 290,000 | -- | 295,191 |
| May 12, 2021 |
Director, President and CEO
Trans History: 14
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 290,000 | -- | 585,191 |
| May 12, 2021 |
Chief Operating Officer
Trans History: 12
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 240,000 | -- | 252,086 |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 7
|
Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 10,000 | -- | -- |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 7
|
Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 5,000 | -- | -- |
| Apr 23, 2021 |
Chief Medical Officer
Trans History: 7
|
Form 3/A | Amendment to an Initial Statement of Beneficial Ownership of Securities | 10,210 | -- | -- |
| Apr 01, 2021 |
Chief Medical Officer
Trans History: 7
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
| Apr 01, 2021 |
Director, President and CEO
Trans History: 14
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 775,000 | -- | 775,000 |
| Apr 01, 2021 |
Chief Operating Officer
Trans History: 12
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
| Apr 01, 2021 |
Chief Financial Officer
Trans History: 9
|
Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.